Roivant Sciences Ltd. (NASDAQ:ROIV)
| Market Cap | $28.01B+90.4% |
| Revenue (ttm) | $41.08M+102.1% |
| Net Income | -$344.35M+7.9% |
| EPS | -$0.54+3.6% |
| Shares Out | 724.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,970,169 |
| Open | $38.86 |
| Previous Close | $38.96 |
| Day's Range | $38.46 - $39.51 |
| 52-Week Range | $19.96 - $42.50 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | $52.17(+34.96%) |
| Earnings Date | Feb 5, 2027 |
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating ROIV in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 5, 2027Earnings report
$ROIV stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ROIV by members of U.S. Congress
| Lisa C. McClainHouse / R | Sale$1.00K – $15.00K | Oct 31, 2025 |
| Lisa C. McClainHouse / R | Sale$1.00K – $15.00K | Oct 30, 2025 |
| Lisa C. McClainHouse / R | Purchase$1.00K – $15.00K | Oct 30, 2025 |
| Lisa C. McClainHouse / R | Purchase$1.00K – $15.00K | Jun 17, 2025 |
Recently reported changes in ROIV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ROIV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ROIV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ROIV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ROIV from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ROIV
| IJHiShares Core S&P Mid-Cap ETF | $754.53M |
| VTIVanguard Morningstar Total Stock Market ETF | $467.37M |
| VBVanguard Morningstar Small-Cap ETF | $418.41M |
| XMMOInvesco S&P MidCap Momentum ETF | $261.76M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $234.19M |
| VXFVanguard Extended Market ETF | $226.81M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ROIV’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrade and Q2 revenue beat offset by significant insider selling; positive clinical and commercial progress provides fundamental support.
Recent Insider Activity
Insider Score Trend Over Time
-38.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| ADPV | Adaptiv Select ETF | 5.89% |
| ADDS | Hedgeye Index Adds ETF | 5.00% |
| TYNE | Direxion Nanotechnology ETF | 4.65% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 4.30% |
| XMMO | Invesco S&P MidCap Momentum ETF | 4.23% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 2.73% |
| PJFM | PGIM Jennison Focused Mid-Cap ETF | 2.50% |
| TEC | Harbor Transformative Technologies ETF (TEC) | 2.36% |
| AAUB | Alpha Architect US Equity 4 ETF | 2.26% |
| MOON | Direxion Moonshot Innovators ETF | 2.05% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 1.86% |
| BBP | Virtus Biotech ETF | 1.79% |
Weight is the stock’s share of each fund’s holdings.
